Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Operating Expenses (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Operating Expenses readings, the most recent being $30885.0 for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 47.32% to $30885.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $127033.0, a 7.04% increase, with the full-year FY2024 number at $123162.0, up 5.73% from a year prior.
  • Operating Expenses hit $30885.0 in Q3 2025 for Goldenwell Biotech, down from $40620.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $920332.0 in Q4 2022 to a low of -$150479.0 in Q4 2021.
  • Median Operating Expenses over the past 5 years was $28751.0 (2022), compared with a mean of $60939.4.
  • The widest YoY moves for Operating Expenses: up 10658.37% in 2021, down 16632.19% in 2021.
  • Goldenwell Biotech's Operating Expenses stood at -$150479.0 in 2021, then surged by 711.6% to $920332.0 in 2022, then crashed by 97.73% to $20872.0 in 2023, then grew by 11.4% to $23251.0 in 2024, then surged by 32.83% to $30885.0 in 2025.
  • The last three reported values for Operating Expenses were $30885.0 (Q3 2025), $40620.0 (Q2 2025), and $32277.0 (Q1 2025) per Business Quant data.